What are the evidence‑based benefits, recommended dosing, and safety profile of oral and intravenous glutathione supplementation in healthy adults?

Glutathione Supplementation: Evidence-Based Benefits and Clinical Applications

Direct Answer

Oral glutathione supplementation at 250-1000 mg/day increases body stores of glutathione in healthy adults, but current clinical guidelines do not recommend routine supplementation for general health purposes—instead, antioxidants should be obtained through food sources. 1, 2

---

Evidence-Based Benefits by Clinical Context

For Healthy Adults (General Population)

• No guideline-supported indication exists for routine oral glutathione supplementation in healthy individuals. The American Cancer Society explicitly recommends obtaining antioxidants through food sources rather than isolated supplements, as clinical trials have failed to demonstrate the cancer risk reduction seen with whole food consumption. 1

• The Cystic Fibrosis Foundation and ESPEN surgical nutrition guidelines both state that insufficient evidence exists to recommend for or against chronic oral glutathione use, noting that data on glutathione as a single substance are limited. 2, 3

• Despite lack of guideline support, one high-quality RCT (2015) demonstrated that oral glutathione at 250-1000 mg/day for 6 months significantly increased glutathione levels in blood (30-35% increase in erythrocytes, plasma, and lymphocytes at high dose), with dose-dependent effects that reversed after washout. 4 This establishes bioavailability but not clinical benefit.

For Specific Medical Conditions

Platinum-Based Chemotherapy Neuropathy Prevention

• Intravenous glutathione 1,500 mg/m² (approximately 2.5-4 g) in 100 mL saline over 15 minutes immediately before each chemotherapy cycle is supported by moderate-quality evidence for preventing cisplatin and oxaliplatin-induced neuropathy. Five small RCTs showed statistically significant reductions in neurotoxicity. 5

• Maximum studied single dose is 2.5 g IV over 15 minutes, administered with each chemotherapy cycle (every 2-3 weeks), not daily. 5

• Critical caveat: The American Society of Clinical Oncology found that glutathione does NOT prevent taxane-induced peripheral neuropathy—a large placebo-controlled trial of 185 patients receiving paclitaxel/carboplatin showed no benefit. 5 This is platinum-specific, not applicable to all chemotherapy.

Critical Illness and Surgical Patients

• For ICU patients requiring parenteral nutrition, glutamine (not glutathione) at 0.2-0.4 g/kg/day (as L-glutamine or 0.3-0.6 g/kg/day alanyl-glutamine dipeptide) is recommended to support glutathione synthesis. 3, 5

• N-acetylcysteine (NAC) 20-50 mg/kg/day is the preferred glutathione precursor for pediatric parenteral nutrition and patients requiring parenteral supplementation, as NAC serves as a substrate for endogenous glutathione synthesis. 5

• Glutamine supplementation at 0.2-0.3 g/kg/day is recommended specifically for burn patients and trauma patients with complicated wound healing, as it supports glutathione synthesis. 1

• Contraindication: Parenteral glutamine is contraindicated in unstable ICU patients with liver and renal failure. 1 The Surviving Sepsis Campaign strongly recommends against glutamine supplementation for general septic patients, as multiple well-designed studies failed to show mortality benefit. 1

---

Dosing Recommendations by Route

Oral Glutathione (When Used Off-Guideline)

• Research-supported dose range: 250-1000 mg/day for increasing body stores, with effects appearing at 1 month and maximizing by 6 months. 4
• Higher doses (1000 mg/day) produced greater increases (30-35% vs 17-29% at lower dose) and showed a >twofold increase in natural killer cell cytotoxicity at 3 months. 4
• Effects reverse after 1-month washout, indicating need for continuous supplementation. 4

Intravenous Glutathione

• For platinum-induced neuropathy prevention: 1,500 mg/m² (max 2.5 g) IV over 15 minutes before each chemotherapy cycle. 5
• Never administer as rapid bolus—15-minute infusion required to minimize infusion-related adverse events. 5
• Frequency: With each chemotherapy cycle (every 2-3 weeks), not daily. 5

Glutathione Precursors (Preferred Approach)

• N-acetylcysteine: 20-50 mg/kg/day for parenteral nutrition patients requiring glutathione support. 5
• L-glutamine: 0.2-0.4 g/kg/day for ICU patients on parenteral nutrition (doses of 10-30 g/24h safely tolerated). 3

---

Safety Profile

Oral Glutathione

• Well-tolerated at doses up to 1000 mg/day for 6 months in the only long-term RCT in healthy adults. 4
• No serious adverse events reported in this trial. 4
• Reversible effects suggest low risk of toxicity. 4

Intravenous Glutathione

• No harmful effects reported in critically ill patients at doses of 10-30 g/24h (for glutamine, which supports glutathione synthesis). 3
• Concerns about glutamate toxicity have not been substantiated, even in head trauma patients. 3
• Infusion-related reactions possible if administered too rapidly—hence the 15-minute infusion requirement. 5

Critical Safety Warnings

• Subcutaneous administration is NOT supported by any evidence and carries risks of injection site reactions, tissue irritation, abscess formation, and unknown absorption/systemic effects. 5
• During active chemotherapy or radiotherapy, most oncologists advise against higher-dose antioxidant supplements, as they may repair oxidative damage to cancer cells that contributes to treatment effectiveness. 1
• No pharmacokinetic data exists for subcutaneous bioavailability, posing significant safety risks. 5

---

Clinical Decision Algorithm

Step 1: Identify the clinical context

• Healthy adult seeking general health benefits → No supplementation recommended; advise food-based antioxidants 1, 2
• Patient receiving platinum-based chemotherapy (cisplatin/oxaliplatin) → Consider IV glutathione 1,500 mg/m² over 15 min before each cycle 5
• Patient receiving taxane chemotherapy → Do NOT use glutathione (ineffective) 5
• ICU patient on parenteral nutrition → Use glutamine 0.2-0.4 g/kg/day or NAC 20-50 mg/kg/day 3, 5
• Burn/trauma patient with complicated wound healing → Use glutamine 0.2-0.3 g/kg/day 1
• Septic patient → Do NOT use glutamine (no mortality benefit) 1

Step 2: Assess contraindications

• Liver or renal failure in unstable ICU patient → Contraindicated 1
• Active chemotherapy/radiotherapy → Avoid high-dose antioxidant supplements 1

Step 3: Select appropriate route and precursor

• Never use subcutaneous route (no safety/efficacy data) 5
• Prefer glutathione precursors (NAC, glutamine) over direct glutathione for parenteral nutrition 5
• Use IV glutathione only for platinum-neuropathy prevention with established protocol 5

---

Common Pitfalls to Avoid

• Do not confuse glutathione with glutamine—they are different compounds with different indications. Glutamine is used in parenteral nutrition to support endogenous glutathione synthesis. 5

• Do not extrapolate oral glutathione benefits to clinical outcomes—while oral supplementation increases body stores 4, guidelines emphasize that isolated antioxidant supplementation has repeatedly failed to replicate benefits seen with whole food consumption. 1, 2

• Do not use glutathione for all chemotherapy-induced neuropathy—it is ineffective for taxanes and evidence is strongest only for platinum agents (cisplatin/oxaliplatin). 5

• Do not assume subcutaneous administration is safe—no sterile pharmaceutical-grade formulations exist for this route, and there is no data on bioavailability or safety. 5

• Do not use glutamine in general septic patients—the Surviving Sepsis Campaign strongly recommends against this based on multiple negative trials. 1